Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
10/16/2020 10/19/2020 10/20/2020 10/21/2020 10/22/2020 Date
1488.5 1497.5 1486.5 1510 1486 Last
4882300 4580900 4040000 4658900 4978000 Volume
+0.61% +0.60% -0.73% +1.58% -1.59% Change
Financials
Sales 2021 1 274 B 12 145 M 12 145 M
Net income 2021 204 B 1 947 M 1 947 M
Net cash position 2021 450 B 4 287 M 4 287 M
P/E ratio 2021 13,4x
Yield 2021 2,84%
Sales 2022 1 346 B 12 836 M 12 836 M
Net income 2022 231 B 2 199 M 2 199 M
Net cash position 2022 578 B 5 507 M 5 507 M
P/E ratio 2022 11,8x
Yield 2022 3,12%
Capitalization 2 760 B 26 386 M 26 314 M
EV / Sales 2021 1,81x
EV / Sales 2022 1,62x
Nbr of Employees 15 883
Free-Float 99,2%
More Financials
Company
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%). 
Sector
Pharmaceuticals
Calendar
10/30Earnings Release
More about the company
Notations Surperformance© of Astellas Pharma Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ASTELLAS PHARMA INC.
10/21ASTELLAS PHARMA INC. : - U.S. FDA Grants Fast Track Designation for ASP0367/MA-0..
AQ
10/20ASTELLAS PHARMA INC. : - New Roxadustat Data in Anemia of Chronic Kidney Disease..
AQ
10/19ASTELLAS PHARMA : China Update – Drug Patents
AQ
10/16ASTELLAS PHARMA : to acquire iota Biosciences
AQ
10/15Nikkei flat as coronavirus resurgence in Europe hits sentiment
RE
10/15ASTELLAS PHARMA : FibroGen to Present New Efficacy and Safety Analyses from Roxa..
AQ
10/14ASTELLAS PHARMA : to Acquire iota Biosciences
BU
10/13ASTELLAS PHARMA : and Seagen Announce Positive Topline Results from Second Cohor..
AQ
10/09ASTELLAS PHARMA : and LabCentral Announce Golden Ticket Winners, Helping Emergin..
AQ
10/02ASTELLAS PHARMA : Celebrates First-Ever Virtual Day of Service to Help Non-Profi..
AQ
09/30ASTELLAS PHARMA : and MBC BioLabs Announce Golden Ticket Competition to Help Bio..
AQ
09/29ASTELLAS PHARMA : Real-World Evidence Studies Provide Further Insight into Negat..
AQ
09/29ASTELLAS PHARMA INC. : Ex-dividend day for interim dividend
FA
09/25ASTELLAS PHARMA : and University of Pittsburgh Announce Research Collaboration f..
AQ
09/24ASTELLAS PHARMA INC. : - Astellas Efforts against the Spread of the Coronavirus ..
AQ
More news
News in other languages on ASTELLAS PHARMA INC.
07/30ASTELLAS PHARMA INC. : Veröffentlichung des Quartalsergebnisses
07/30ASTELLAS PHARMA INC. : publication des résultats trimestriels
05/28Basileas klinische Studien liegen trotz Corona mehr oder weniger im Zeitplan
05/11ASTELLAS PHARMA INC. : Veröffentlichung des Jahresergebnisses
05/11ASTELLAS PHARMA INC. : publication des résultats annuels
More news
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 2 275,00 JPY
Last Close Price 1 486,00 JPY
Spread / Highest target 81,7%
Spread / Average Target 53,1%
Spread / Lowest Target 14,4%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.-20.53%26 812
JOHNSON & JOHNSON-1.33%378 942
ROCHE HOLDING AG-4.73%283 006
PFIZER INC.-4.31%206 049
MERCK & CO., INC.-14.16%197 458
NOVARTIS AG-16.89%186 106